**Yersinia pestis** antibiotic resistance: a systematic review

**Chen Lei**1,2, **Suresh Kumar**3

1Pharmacy Department, Jiangsu Vocational College of Medicine, Yancheng, China
2Doctor of Philosophy in Biomedicine, School of Graduate Studies, Management and Science University, Shah Alam, Malaysia
3Department of Diagnostic and Allied Health Science, Faculty of Health and Life Sciences, Management and Science University, Shah Alam, Malaysia

**ABSTRACT**

*Yersinia pestis*, the cause of plague and a potential biological weapon, has always been a threatening pathogen. Some strains of *Y. pestis* have varying degrees of antibiotic resistance. Thus, this systematic review was conducted to alert clinicians to this pathogen’s potential antimicrobial resistance. A review of the literature was conducted for experimental reports and systematic reviews on the topics of plague, *Y. pestis*, and antibiotic resistance. From 1995 to 2021, 7 *Y. pestis* isolates with 4 antibiotic resistance mechanisms were reported. In *Y. pestis* 17/95, 16/95, and 2180H, resistance was mediated by transferable plasmids. Each plasmid contained resistance genes encoded within specific transposons. Strain 17/95 presented multiple drug resistance, since plasmid 1202 contained 10 resistance determinants. Strains 16/95 and 2180H showed single antibiotic resistance because both additional plasmids in these strains carried only 1 antimicrobial determinant. Strains 12/87, S19960127, 56/13, and 59/13 exhibited streptomycin resistance due to an *rpsl* gene mutation, a novel mechanism that was discovered recently. *Y. pestis* can acquire antibiotic resistance in nature not only via conjugative transfer of antimicrobial-resistant plasmids from other bacteria, but also by gene point mutations. Global surveillance should be strengthened to identify antibiotic-resistant *Y. pestis* strains by whole-genome sequencing and drug susceptibility testing.

**Keywords:** Drug resistance; Plasmids; *rpsl* gene mutation; *Yersinia pestis*

**Introduction**

*Yersinia pestis*, an obligate parasite and Gram-negative bacterium, is the causative agent of plague and has killed an estimated 200 million people in 3 major pandemics in the 14th, 17th, and 19th centuries. The first pandemic, known as the Black Death, killed more than 30% of Europe’s population. Alexandre Yersin, a bacteriologist, discovered it during a plague investigation in Hong Kong in 1894 [1]. Plague is now rare, and it is generally considered as a disease of the past. However, it still appears in many areas, including Asia, Africa, and...
America, in the 21st century, and it remains a threat to public health [2]. Every year, at least 2,000 cases of plague are documented. Y. pestis can grow within a wide range of temperatures, and its optimal pH for growth is 7.2 to 7.6 [3]. It dies rapidly when exposed to ultraviolet light, intensive desiccation, temperatures exceeding 40°C [4]. It is generally accepted that Y. pestis evolved from *Yersinia pseudotuberculosis* 1,500–2,000 years ago [5]. However, Y. pestis was recently found in the remains of a hunter-gatherer from 5,000 years ago via ancient DNA analysis, suggesting that Y. pestis emerged about 7,000 years ago, which is substantially older than considered before [6]. This early strain isolated from ancient human remains seems to be less virulent and less contagious than later strains of *Y. pestis* [6]. *Y. pestis* strain CO92 was the first to be sequenced [7], and other strains have been sequenced subsequently [8–11]. Specific characteristics of the genome and molecular mechanisms of *Y. pestis* contribute to its infection of fleas, virulence, and subsistence against the host immune response [12].

According to biologists, many wild animal species are highly susceptible to *Y. pestis*. It lives in small rodents that are mostly found in rural and semi-rural areas of Africa, Asia, and the United States. The effects of plague on these populations are unknown, but certain characteristics make rodent species more vulnerable to the disease. However, due to a series of gene mutations, gene acquisition and loss, the molecular mechanisms and lifestyle of *Y. pestis* have changed dramatically [5]. *Y. pestis* contains a particular group of virulence factors that enable colonization in the flea and allow growth and subsistence in mammal macrophages [13]. For instance, it evolved to lose major genes for better adaptation to the flea vector. Its virulence determinants for hosts are mainly contained on 3 well-characterized plasmids (pYV/pCD1, pPla/pPCP1 and pFra/pMT), as well as in the pathogen’s chromosome [12]. Specific virulence proteins are encoded, such as Yersinia outer membrane proteins (Yops) and the protease Pla, which cause host cell death and escape from phagocytosis by macrophages through multiple sophisticated strategies [14]. In addition to the well-known virulence genes, novel virulence factors have been detected in recent years. With the introduction of genome-wide fitness profiling and mutant screening methods, more genes were identified as being involved in bacterial intracellular survival in the early stage of bubonic plague, as well as in the infection process [15,16]. Gene sequencing not only revealed the genetic information of *Y. pestis*, but also phylogeographic information on its evolution. An analysis of 345 core genome sequences from *Y. pestis* based on the National Center for Biotechnology Information (NCBI) international database and genome sequencing revealed 3,315 single-nucleotide polymorphisms (SNPs). Combining the results of phylogenetic trees and strain foci, the evolution of *Y. pestis* mainly occurred in Asia, including China, Mongolia, and Middle East [11].

**Materials and Methods**

**Literature Search**

The systematic review follows the Preferred Reporting Items of Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Figure 1). A literature search was performed in Medline, Embase, and Web of Science from their inception to December 2021. Firstly, articles were identified using the key terms “*Yersinia pestis*” or “Plague.” These words were then combined in a second search with the subject headings “Antibiotic Resistance,” “Antimicrobial Resistance,” or “Drug Resistance” to identify references related to *Y. pestis* antibiotic resistance.

In total, 1,475 potentially related publications were identified through the database search. Twenty-four other articles were identified via a manual review of article references. As a result, 1,499 articles were screened based on the title, abstract, and content. All publications that contained content on the life cycle/transmission of *Y. pestis* and its antibiotic resistance were included, along with those that dealt with the clinical manifestations and diagnosis, latest treatment, and prevention of plague. Finally, 68 full-text articles were included in this systematic review. The flow chart of the literature search is shown in Figure 1.

**Results**

**Epidemiology**

As an obligate parasite, the life cycle of *Y. pestis* consists of rodents, transmission from fleas to animal reservoirs, and transmission between mammal hosts. Fleas feed on a rodent infected with *Y. pestis*, which survive within the flea gut. The moving vector then delivers the bacteria intradermally through a bite into a new mammalian host. Lagomorphs, artiodactyls, carnivores, hyracoids, insects, marsupials, and primates can be infected [4]. The movement of *Y. pestis* through different types of mammals promotes the distribution of plague between areas [17]. Humans can be infected with *Y. pestis* by flea bites, contact with infected animals, and intake of undercooked contaminated meat. Therefore, people surrounded by animals are more likely to be infected. Moreover, plague can be transmitted between people by respiratory droplets from the coughs of infected
When *Y. pestis* enters *in vivo*, the infection begins (Figure 2). Firstly, it can enter neutrophils and macrophages actively or passively. It has generally been thought that *Y. pestis* bacteria are killed in neutrophils, while they can live on and proliferate within macrophages [19]. Nevertheless, it has been proven that *Y. pestis* can also survive and duplicate before the type III secretion system (T3SS) is upregulated at the body temperature of fleas [20]. After that, infected neutrophils would be ingested by macrophages in a cleaning process known as efferocytosis [12]. During the efferocytosis period, a cytokine named IL-1RA is secreted, which blocks the inflammatory response and upregulates the T3SS [21]. This may partly explain why *Y. pestis* adapts to the extracellular lifestyle with antiphagocytic abilities even after escaping from macrophages. Thus, it is difficult for phagocytes to ingest the bacteria in the late stage of the infection. As the bacteria arrive at the target organs via lymphatic system, virulence factors such as Yops translocate into the host cells through T3SS, which both activates the signal-transducing pathway and promotes contact between Yops and host cells [13].

**Detection and Diagnosis of Plague**

A rapid diagnosis is required to ensure that plague-suspected patients receive timely medical administration to reduce the risk of mortality. Several biological diagnostic tests have been developed to identify *Y. pestis*. Isolation of this pathogen from clinical specimens remains the gold standard for plague diagnosis according to World Health Organization recommendations [12]. The use of selective cefsulodin-irgasan-novobiocin medium under an appropriate culture temperature are essential to isolate the bacteria [22]. Nonetheless, this method is quite time-consuming (about 3 to 5 days) and labor-intensive [12]. Therefore, automatic detection methods have been developed for faster diagnostic results. The F1 antigen has been widely adopted as the target for discriminating *Y. pestis*, since it is the typical immunogenic protein of the pathogen [23–25]. The F1 dipstick assay and enzyme-linked immunosorbent assay have been developed to identify the F1 antigen, and these methods have been proven practical with trained staff at local points of care [12]. However, these methods that depend on an immunological reaction have some limitations, including low sensitivity and delayed
The detection results may be negative if samples are collected in the early stage of infection when massive multiplication has not occurred inside the host [27]. Other detection methods, such as phage lysis and mass spectrometry, are sometimes misleading [12,28].

Molecular genetic tests have been developed to reduce delays in detection and increase the sensitivity of diagnostics. Conventional polymerase chain reaction (PCR) targeting the caf1, pla, yopM, and inv gens can offer results within 3 to 4 hours [12]. Nonetheless, PCR-based diagnostic methods need to be performed in a laboratory with level II biosafety, technical expertise, and specialized instruments [29,30]. Thus, portable real-time quantitative PCR thermocyclers have been invented to enable medical staff to perform tests in the field without special equipment [18]. The recombinase polymerase assay and loop mediated isothermal amplification (LAMP) assay have been developed to make the tests easier and more efficient than conventional PCR [26]. A LAMP assay pair on caf1 and 3a has been described, but it was only tested in artificially spiked human blood samples [26]. Another LAMP assay targeting the caf1 gene was developed for detection of Y. pestis in plague biological samples. The sensitivity and specificity of this test were quite reliable compared with the gold standard [31]. In fact, the diagnosis of Y. pestis is generally confirmed by a combination of several detection methods. Culture-based identification offers provisional results, while molecular biology tests or antigens detection tests provide more precise results [27].

Clinical Manifestations
There are numerous specific clinical manifestations of plague depending on the route of transmission [32]. Three major types of plague are generally reported: bubonic, septicemic, and pneumonic [33]. As the most frequent form, bubonic plague is characterized by swollen regional lymph nodes and usually occurs after infected flea bites. In some cases, patients may suffer red and hot skin, headache, fever (up to 39°C), chills, malaise, and severe pain of the lymph nodes near the flea-bite region [18]. Nausea, emesis, and dizziness are less-common manifestations. Without treatment in time, Y. pestis can spread to the lungs and other organs, leading to more severe clinical symptoms [4]. Septicemic plague occurs when the blood is infected. This type may arise primarily and secondarily to bubonic plague, generally accompanied by systemic symptoms, including sudden chills, high fever, multiple organ failure, nausea, and diarrhea. Disseminated intravascular coagulation, purpura and acral cyanosis, necrosis, and hemorrhage in the skin and serosal surfaces may present later.

The most virulent and dangerous type is pneumonic plague, which results in nearly 100% mortality and is easily transmissible via airborne droplets. The incubation period is quite short, usually 1 to 3 days, after large-scale exposure to Y. pestis. This form manifests with the abrupt onset of chills, fever, weakness, headache, chest discomfort, severe coughing, and sometimes bloody or watery mucus [34].

Other forms of plague are rarely reported. Pharyngeal plague sometimes occurs when people eat uncooked meat contaminated by Y. pestis [4]. This form of plague may present with distinctive clinical symptoms, including acute pharyngitis and tonsillitis, accompanied by enlargement of the cervical lymph nodes [35]. Gastrointestinal plague is
transmitted in the same way, and it manifests as vomiting, abdominal pain, diarrhea, tenesmus, and mucous stool accompanied with systemic symptoms [36]. Cutaneous plague is also described in rare cases. The infection is transmitted through flea bites, with the rapid formation of herpes and pustules [18].

**Treatment**

Although plague, especially the pneumonic form, can cause high and rapid mortality, the disease can be treated with early antimicrobial treatment [37]. Based on a systematic review of 762 published clinical cases from 1937 to 2019, aminoglycosides, tetracyclines, fluoroquinolones, and sulfonamides proved to be effective against plague. However, the case fatality rate of patients treated with sulfonamides was slightly higher, which is likely due to the time period, since sulfonamides were generally used from 1937 to 1949. Fluoroquinolones have been exclusively administered since the 1980s, when they were developed [38]. According to the latest recommendations on antimicrobial treatment for plague from the Centers for Disease Control and Prevention (CDC), aminoglycosides and fluoroquinolones are the mainstays of antimicrobial treatment for plague, while tetracyclines, chloramphenicol, and trimethoprim-sulfamethoxazole (TMP-SMX) could also be options for treatment depending on the age and pregnancy status of the patient [37]. Nevertheless, a study of plague in Vietnam revealed that patients treated with TMP-SMX had a longer duration of fever and some developed complications [38]. Furthermore, the World Health Organization does not recommend chloramphenicol as plague therapy considering its severe adverse effects, including reversible bone marrow suppression, aplastic anemia, and “gray baby” syndrome. Tetracyclines have few major adverse events, but they are contraindicated for pregnant women and infants [39]. Table 1 displays the first choices of treatment protocols for plague from the CDC [37]. Apart from doxycycline (for bubonic and pharyngeal plague), the other antibiotics in the table can be used to treat all forms of plague.

**Prevention**

Evidence shows that pneumonic and septicemic plague spread more easily from person to person because bloody sputum and aerosols mixed with *Y. pestis* are infectious [40]. Preventive measures comprise physical isolation, oral prophylactic antibiotics, and vaccines.

Patients are recommended to stay physically isolated for the initial 48 hours during antibiotic treatment until they improve clinically. Face masks, gloves, and eye protectors are standard precautions against respiratory droplets [41].

Close contacts (<2 m) of patients infected with pneumonic plague and individuals exposed to airborne droplets are at high risk of infection [34]. Therefore, they are suggested to receive orally administered ciprofloxacin, levofloxacin,

---

**Table 1. Current recommended treatment protocol from the CDC**

| Antibiotic                        | Dose                  | Duration (d) | Route of administration |
|-----------------------------------|-----------------------|--------------|-------------------------|
| Ciprofloxacin                     | 400 mg/8 h            | 10 mg/kg per 8 or 12 h (maximum 400 mg/dose) | 7–10 IV |
|                                   | 750 mg/12 h           | 15 mg/kg per 8 or 12 h (maximum 500 mg/dose per 8 h or 750 mg/dose per 12 h) | PO |
| Levofoxacin                       | 750 mg/24 h           | Weight < 50 kg: 8 mg/kg per 12 h (maximum 250 mg/dose) | 7–10 IV or PO |
|                                   |                       | Weight ≥ 50 kg: 500–750 mg per 24 h | |
| Moxifloxacin                      | 400 mg/24 h           | Alternative option | 7–10 IV or PO |
| Doxycycline (for bubonic and pharyngeal plague) | 200 mg loading does, then 100 mg/12 h | Weight < 45 kg: 4.4 mg/kg loading dose, then 2.2 mg/kg every 12 h (maximum 100 mg/dose) | 7–10 IV or PO |
| Gentamicin                        | 5 mg/kg every 24 h    | 4.5–7.5 mg/kg every 24 h | 7 IV or IM |
| Streptomycin                      | 1 g/12 h              | 15 mg/kg every 12 h (maximum 1 g/dose) | 7 IV or IM |

Based on [37].

Pediatric regimens are for children aged ≥ 1 month to ≤ 17 years.

CDC, Centers for Disease Control and Prevention; IV, intravenous; PO, by mouth; IM, intramuscular.

---

https://doi.org/10.24171/j.phrp.2021.0288
doxycycline, and moxifloxacin as the first options for 7 days according to the CDC recommendations [37]. However, in a mass casualty setting, doxycycline, ciprofloxacin, and tetracycline are suggested as the preferred choice for postexposure prophylaxis based on the suggestions of Working Group on Civilian Biodefense. In contrast, gentamicin or streptomycin are recommended when a modest number of patients need treatment [42].

Vaccination is another precautionary method against the plague. A live attenuated vaccine was invented and applied in 1931 in Madagascar and remained in use in Russia and China [43]. In addition, a killed whole-cell vaccine was licensed and used by the United States Army. However, it was not continued since studies proved that this type of vaccine was only effective against bubonic plague without the ability to prevent pneumonic plague [34]. Most advanced research in recent years focused on molecular vaccines against pneumonic plague. The F1 and V antigens of Y. pestis were combined, since some strains do not contain the F1 antigen [44]. Animal trials showed that 2 doses of the F1/V vaccine could completely protect mice from pneumonic and bubonic plague. Nevertheless, no tests of the F1-V were conducted in humans [12]. Additionally, DNA vaccines have been developed as part of a prime-boost strategy by attenuating Y. pestis strains with genetic engineering, but none have progressed to the clinical stage [4]. An oral vaccine with live attenuated Y. pseudotuberculosis strains, designated as Yptb5, was recently developed. Although this mutant can provide complete protection against a pulmonary challenge with 5.5×10^8 colony-forming units (CFU) of Y. pestis, while partial protection (50% survival) against 100LD50 of Y. pestis [45].

Antibiotic Resistance
Antibiotic resistance or antimicrobial resistance (AMR) refers to the ability of microbes (including bacteria, fungi, and parasites) to resist antibiotics, making antimicrobial drugs ineffective [46]. Since antimicrobials are the primary options for plague treatment and prophylaxis, antibiotic resistance in Y. pestis increases the risks posed by this disease and makes it more challenging to control. Understanding the mechanism of AMR in Y. pestis is the key to solving this problem.

**Y. pestis strains with antibiotic resistance**
To date, 5 Y. pestis strains with unique AMR and multidrug resistance (MDR) were isolated and identified in Madagascar with complete genome sequencing (Table 2) [47]. In addition, 1 streptomycin-resistant strain of the bacterium was found, and the genome was recently sequenced in the Tibetan region of China [48].

**Y. pestis** strains 12/87, 56/13, 59/13, and S19960127 exhibited high streptomycin resistance due to a novel mechanism, namely a ribosomal protein S12 gene (rpsl) mutation. For isolates 56/13, 59/13, and 12/87, the minimum inhibitory concentrations (MICs) were over 1,024 μg/mL, sharing 1 SNP (position 215,373 in the CO92 reference genome). However, strain 12/87 was highly distinct from strains 56/13 and 59/13 based on a phylogenetic analysis. However, as the first strain discovered exhibited the novel mechanism of antibiotic resistance, S19960127 displayed quite high resistance to streptomycin (MIC = 4,096 μg/mL). It shared the same SNP (215373) as those found in Madagascar [47,48].

Plasmid-mediated high-level resistance to antibiotics was identified in strains 17/95, 16/95, and IP2180H (Table 2). Strain 17/95 presented resistance to at least 8 antimicrobial agents to different degrees, including streptomycin (MIC > 2,048 μg/mL), ampicillin (MIC = 2,048 μg/mL), kanamycin (MIC = 2,048 μg/mL), spectinomycin (MIC = 2,048 μg/mL), sulfonamides (MIC = 1,024 μg/mL), tetracycline (MIC = 1,024 μg/mL), minocycline (MIC = 512 μg/mL) and chloramphenicol (MIC = 128 μg/mL). However, it was susceptible to TMP [49]. Y. pestis 16/95 was only resistant to streptomycin (MIC = 1,024 μg/mL) and remained susceptible to others therapeutics or prophylactics against plague. Strain IP2180H exhibited high-level resistance to doxycycline (MIC > 16 μg/mL), while it was susceptible to other antibiotics such as ampicillin, kanamycin, moxifloxacin, levofloxacin, and imipenem [50].

Apart from the above strains, some reported AMR/MDR

### Table 2. Strains of Yersinia pestis with antimicrobial resistance

| Type of strains | Location of isolation | Year | Host of isolation | Resistance phenotype | Mechanism |
|-----------------|-----------------------|------|-------------------|----------------------|-----------|
| 12/87           | Andapa in Madagascar  | 1987 | Human             | Streptomycin         | rpsl gene mutation |
| 17/95 (IP275)   | Ambalavao in Madagascar | 1995 | Human             | Multiple drug resistance | Plasmid IP1202 |
| 16/95           | Amphitana in Madagascar | 1995 | Human             | Streptomycin         | Plasmid IP1203 |
| S19960127       | Tibet in China        | 1996 | Human             | Streptomycin         | rpsl gene mutation |
| IP2180H         | Antananarivo in Madagascar | 1998 | Rat               | Doxycycline          | Plasmid pIP2180H |
| 56/13, 59/13    | Faratsiho in Madagascar | 2013 | Humans             | Streptomycin         | rpsl gene mutation |

https://doi.org/10.24171/j.phrp.2021.0288
strains, however, did not provide a genetic basis and transferability of resistance \[51,52\]. For instance, an MDR \textit{Y. pestis} strain, MNG 3122, was isolated in Mongolia from a marmot. However, its antibiotic susceptibility profile was different from that of \textit{Y. pestis} 17/95. It presented drug resistance to gentamicin, tetracycline, doxycycline, TMP-SMX, and chloramphenicol \[52\]. In addition, some AMR strains were discovered during 1996 to 1998 in Madagascar, including ampicillin-resistant and chloramphenicol-resistant isolates from a clinic in Mahajanga District. A tetracycline-resistant isolate from a rat and ampicillin-resistant isolate from a flea were discovered in Antananarivo District \[51\].

Recent studies on the detection of the strains of \textit{Y. pestis} with AMR have been conducted (Table 3) \[53–55\]. PCR and susceptibility tests were primarily used. In the PCR method, various AMR-associated genes were targeted to determine the strains with resistance based on the resistance phenotype of \textit{Y. pestis} of interest in a particular study. The results were all negative, as listed in Table 3 \[53–55\].

**Transferability of antibiotic resistance in \textit{Y. pestis}**
The horizontal transfer of DNA between unrelated organisms is a significant source of variation that leads to new strains of bacterial pathogens. As discussed above, 3 isolates (17/95, 16/95, and IP2180H) presented antibiotic resistance attributed to conjugative plasmids with high rates of transferability, which could be spread to endemic and foreign plague populations, as well as other bacteria, in the same way \[4\]. These plasmids can be transferred horizontally along with other transferable elements, including transposons and integrons, leading to increased phenotypic diversity \[56\].

As a member of the \textit{A/C} incompatibility group of plasmids, the antibiotic plasmid pIP1202 of \textit{Y. pestis} 17/95 can transfer to \textit{Y. pestis} 6/69cN and \textit{Escherichia coli} K802N at frequencies of $1.5 \times 10^{-2}$ and $1 \times 10^{-2}$ per donor CFU, respectively. Meanwhile, pIP1202 can retransfer from \textit{E. coli} to \textit{Y. pestis} and \textit{E. coli} at frequencies of $1.1 \times 10^{-4}$ and $5.7 \times 10^{-5}$, respectively. The lack of stability of pIP1202 in \textit{E. coli} can be attributed to the lower frequency of its transfer from \textit{E. coli} to other strains \[49\].

As for the self-transferable plasmid pIP1203 in \textit{Y. pestis} 16/95, high-frequency transfers were observed from 16/95 to \textit{Y. pestis} 6/69cN and \textit{Y. pseudotuberculosis} IP32790cN at frequencies of $3 \times 10^{-1}$ and $1 \times 10^{0}$ per donor CFU, respectively. Moreover, retransfer of the plasmid pIP1202 occurred from \textit{Y. pestis} 6/69cN to \textit{Y. pestis} 6/69cNR and \textit{Y. pseudotuberculosis} IP32790cNR at frequencies of $2 \times 10^{-1}$ and $5 \times 10^{-1}$ per donor CFU, respectively. Plasmid pIP1203 was found to belong to the \textit{IncP} group \[57\].

The mobile plasmid pIP2180H (a member of the \textit{IncH} group)
can transfer from *Y. pestis* IP2180H to *Y. pestis* CO92 (1.5×10⁻¹ per donor CFU), *Y. pseudotuberculosis* (5×10⁻² per donor CFU) and *E. coli* (2×10⁻¹ per donor CFU) at quite high transfer frequencies [50].

For strains carrying mutated rpsl genes, a study documented that these AMR *Y. pestis* isolates can be transmitted among individuals via respiratory droplets during a pneumatic plague outbreak [47]. Since bubonic plague can cause secondary pneumatic plague without appropriate treatment, an immediate surveillance system seems quite important to detect and identify patients infected with AMR strains.

**Mechanisms of antibiotic resistance in *Y. pestis***

**Plasmid-mediated antibiotic resistance**

Plasmid IP1202 (182913bp) in *Y. pestis* 17/95 confers the ability to produce a series of proteins that inactivate antimicrobial agents. Its resistance mechanisms have constantly been revealed at the molecular level, as presented in Table 4 [42,49]. As this isolate remained susceptible to TMP, synergism did not occur between sulfonamides and TMP for plague treatment [42]. Some of the antibiotic resistance genes, including *aadA*, *sul1*, *tetRA*, and *bla<sub>TEM-1</sub>*, were located in the Tn21 transposon [58], which has been commonly found as the carrier of diverse resistance genes [59].

Streptomycin resistance in *Y. pestis* 16/95 was due to the plasmid pIP2103 (40 kbp), in which the *strA* (801 bp) and *strB* (834 bp) genes encoded aminoglycoside 3”-O-phosphotransferase [aph(3”)-I] and a 6-O-phosphotransferase [aph(6)-I] [57]. These 2 determinants were part of the Tn5393 transposon, which is generally found in phytopathogenic bacteria, such as *Snodgrassella alvi*, *Salmonella enterica serovar Typhimurium*, and *Aeromonas* spp. [60–62]. The inverted terminal repeat (IR), which is frequently found at the same position in the *str* genes in various DNAs, was identified downstream from the *strB* genes. Additionally, a partial sequence of the *tnpR* gene of Tn5393 was located upstream from *strA*. The sequences 1R-tnpR-*strA*-strB-1R were inserted in the R751 backbone [42].

*Y. pestis* IP2180H exhibited single resistance to doxycycline and susceptibility to levofloxacin, moxifloxacin, kanamycin, ampicillin, and imipenem. An additional 171 kbp plasmid was discovered in the strain, designated pIP2180H. Its antibiotic resistance was conferred by the production of tetracycline efflux protein encoded by *tetB* genes located in the Tn10 transposon in the plasmid. Tn10 also carried *tetR* and *tetC*, which coded for regulators. It was also highly homologous to the pB71 plasmid, a multidrug-resistant plasmid in a *Salmonella enterica* strain. However, the pIP2180H plasmid did not present resistance to the same antimicrobial agents as the *S. enterica* strain did [50].

**Gene mutation-associated streptomycin resistance**

As a first-line treatment option against plague, streptomycin can bind to the aminoacyl-tRNA recognition site of 16S rRNA (rrs), impairing translational proofreading and leading to the blockade of protein synthesis and subsequent cell death of sensitive bacteria [63]. Ribosomal protein S12 (rpsl) increases the stabilization of the high-order pseudoknot structure formed by rrs; therefore, amino acid substitutions in the *rpsl* protein influence the conserved structure of rrs and induce the failure of interactions between streptomycin and rrs, conferring high-level streptomycin resistance [48,64].

Based on whole-genome sequencing and alignment analysis with the CO92 strain, 4 isolates (56/13, 59/13, 12/87 and S19960127) were found to have an rpsl gene mutation at 128 bp, resulting in the amino acid substitution of Lys to Arg at site 43 (K43R) in the rpsl protein [48]. Subsequently, as mentioned before, this mutation disrupted streptomycin binding to rrs by altering its tertiary structure.

**Table 4. Antibiotic resistance determinants of the pIP1202 plasmid**

| Resistance phenotype | Mechanism | Resistance gene |
|----------------------|-----------|-----------------|
| β-lactams            | A TEM-1 penicillinase | *bla<sub>TEM-1</sub>* |
| Ampicillin           | efflux | *tetRA<sub>classA</sub>* |
| Tetracycline         | Type I chloramphenicol acetyltransferase | *catI* |
| Phenics              | Dihydropteroate synthase | *sul1, sul2* |
| Chloramphenicol      | A TEM-1 penicillinase | *bla<sub>TEM-1</sub>* |
| Sulfonamides         | Type I chloramphenicol acetyltransferase | *catI* |
| Aminoglycosides      | Dihydropteroate synthase | *sul1, sul2* |
| Kanamycin            | Type I 3’-aminoglycoside phosphotransferase | *aphA, aadA, strAB* |
| Streptomycin         | 3’-9-aminoglycoside adenylyl transferase | *aphA, aadA, strAB* |
| Spectinomycin        | Type I 3’-aminoglycoside phosphotransferase | *aphA, aadA, strAB* |

Based on [42,49].
Mutations associated with streptomycin resistance have been consistently identified in the \textit{rpsl}, \textit{rrs}, and \textit{gidB} genes in \textit{Mycobacterium tuberculosis} (MTB) since 1993 in diverse geographic localities [65]. In contrast, this mechanism of AMR in \textit{Y. pestis} was never reported until 2021, while \textit{Y. pestis} strains containing mutated \textit{rpsl} genes have existed since 1987 according to recent studies [47]. It is probable that detecting strains with a single method (Table 3) [53–55], such as PCR for target genes in plasmids, would reduce the accuracy of streptomycin susceptibility monitoring since it may have missed gene-mutated isolates.

The reasons for the \textit{rpsl} gene mutation were not further investigated through \textit{in vivo} or \textit{in vitro} tests. However, a study about streptomycin resistance in MTB isolates in Nepal assumed that the inappropriate practice of streptomycin monotherapy for MTB in the region was an important factor [63]. As a first-line treatment option for plague, streptomycin is easier to access in developing countries, leading to its wide application in clinical settings, which probably caused the drug-induced gene mutation.

Two strains (17/95, S19960127) have complete genome data in the GenBank, while strains 16/95 and IP2180H only had sufficient gene annotations of specific plasmids. Information on the genes associated with AMR is listed in Table 5.

\textbf{Other possible mechanisms of drug resistance}

Bacterial membrane vesicles (BMVs) have recently been investigated to clarify their connection with antibiotic resistance in pathogenic and non-pathogenic bacteria. They are released by bacteria themselves. A study showed that BMVs could transform bacteria with genes encoding enzymes, resulting in their dissemination and increased AMR. Eddy et al. [66] found that the BMVs of \textit{Y. pestis} contain a penicillin-binding protein activator that regulates peptidoglycan synthesis. However, detailed the mechanism of BMVs against antibiotics was not investigated in that study.

\textbf{Discussion}

Based on the mechanism of AMR/MDR in strains 17/95, 16/95, and IP2180H, it can be inferred that the transposons cause the transmission of antibiotic resistance genes in bacteria. Ten resistance determinants were identified in pIP1202, mostly encoded within the Tn21 transposon, resulting in MDR. In contrast, all the antibiotic resistance-associated genes in pIP1203 and pIP2180H were characterized in Tn5393 and Tn10, respectively. The 3 transposons identified in \textit{Y. pestis} are typical carriers of AMR genes, which have been widely discovered in various bacteria [59]. Tn10 is a composite transposon, while Tn5393 and Tn21 are non-composite transpositions. The former type, carrying drug resistance genes, poses the most serious challenge for treatment against infectious diseases since these transposons allow bacteria to survive toxic compounds created by humans [67]. However, non-composite transposons play a very important role in the genetic evolution of bacteria and the spread of AMR due to transpositions in the transposons, which can cause the increase and decrease of bacterial virulence [59]. As a result, actions should be taken to prevent the transmission of these mobile elements among bacteria.

To date, there was not sufficient evidence confirming the reason for the \textit{rpsl} gene mutation in \textit{Y. pestis} with streptomycin resistance. However, cases in Madagascar that occurred in 2013 excluded streptomycin application-induced gene mutation, since sputum samples from patients surviving from plague were collected before the administration of streptomycin [47,48]. As for the cases in 1996 in Qinghai-Tibet plateau, 4 people were involved in the plague outbreak and the S19960127 strain was isolated from the necropsy organ samples from 1 patient who received streptomycin treatment for 8 days [48]. It seems that further research should be conducted in \textit{in vivo} or \textit{in vitro} to clarify the origin of streptomycin resistance in \textit{Y. pestis}.

As discussed above, the frequent use of streptomycin in plague treatment may have played an important role in the emergence of this mutation. Since drugs mediate gene mutations, vaccines and antibiotics targeting novel gene points (such as DNA adenine methyltransferase) may be an inevitable choice for defeating the bacteria [68].

It should be noticed that no plague patients in Tibet who were treated with unified administration (intramuscular streptomycin, oral TMP/SMX, oral tetracycline) survived, while all cases given a similar treatment recovered in Madagascar in 2013 [47,48]. The significant difference in the treatment effects between the 2 outbreaks, on one hand, corresponded to the streptomycin susceptibility tests, in which the S19960127 strain exhibited higher streptomycin resistance than 59/13 and 56/13. On the other hand, more advanced medical conditions probably contributed to the higher cure rate of plague in the more recent outbreak.

Last, it should be noted that the 3 patients infected with pneumonic plague in Tibet died quite soon after treatment (3 to 8 days) due to inappropriate medication. Not only does this fact illustrate the high mortality of pneumonic plague, but it also underscores the importance of rapid detection of antibiotic resistance of strains isolated from people in the early stage of infection. Drug susceptibility monitoring of \textit{Y. pestis} isolates should not only include whole-genome sequencing to identify the well-known resistance genes, but
| Strain | Name of the genome | Accession | Size (Mb) | GC% | Protein | Start | Stop | Locus | Locus tag | Protein product | Length | Protein name |
|--------|-------------------|-----------|-----------|------|---------|-------|------|-------|----------|-------------|---------|--------------|
| 17/95  (IP275) | Plasmid pIP1202 | CP000603.1 | 0.18 | 52.9 | 212 | 32222 | 33037 | aphA | YpIP275_ pIP1202_0052 | ABO42185.1 | 271 | Aminoglycoside 3’-phosphotransferase (plasmid) |
|        |                   |           |          |      |         |       |      |       |          |             |         |              |
|        |                   |           |          |      | strA   | 34715 | 35518 | YpIP275_ pIP1202_0055 | ABO42054.1 | 267 | Streptomycin resistance protein A (plasmid) |
|        |                   |           |          |      | strB   | 35518 | 36354 | YpIP275_ pIP1202_0056 | ABO42239.1 | 278 | Streptomycin resistance protein B (plasmid) |
|        |                   |           |          |      | cat    | 40824 | 41483 | YpIP275_ pIP1202_0063 | ABO42042.1 | 219 | Chloramphenicol acetyltransferase (plasmid) |
|        |                   |           |          |      | strA   | 48941 | 49756 | YpIP275_ pIP1202_0073 | ABO42075.1 | 271 | Dihydropteroate synthase (plasmid) |
|        |                   |           |          |      | strA   | 141580| 142440| YpIP275_ pIP1202_0175 | ABO42128.1 | 286 | Beta-lactamase (plasmid) |
|        |                   |           |          |      | tetA   | 147544| 148728| YpIP275_ pIP1202_0182 | ABO42139.1 | 394 | Tetracycline resistance protein TetA, class D (plasmid) |
|        |                   |           |          |      | tetR   | 148824| 149480| YpIP275_ pIP1202_0183 | ABO42071.1 | 218 | Tetracycline repressor protein TetR, class D (plasmid) |
|        |                   |           |          |      | suI    | 152529| 153368| YpIP275_ pIP1202_0188 | ABO42234.1 | 279 | Dihydropteroate synthase (plasmid) |
|        |                   |           |          |      | aadA   | 153873| 154883| YpIP275_ pIP1202_0190 | ABO42050.1 | 336 | Aminoglycoside adenyllytransferase (plasmid) |
| S19960127 | Chromosome | NZ_CP045640.1 | 4.55 | 47.5 | 3849 | 4461357 | 4461731 | rpsL | S96127_RS21075 | WP_200911418.1 | 124 | 30S ribosomal protein S12 |
|        | Plasmid pIP1203 | HG326189 | 0.047 | 64.5 | 50 | 612 | 1415 | strA | - | SPF31211.1 | 267 | Aminoglycoside 3’-phosphotransferase |
|        |                   |           |          |      |       |       |      | strB | - | SPF31212.1 | 201 | Aminoglycoside 3’-phosphotransferase |
| IP2180H | Plasmid pIP2180H | ERS1681497 | 0.17 | 45.4 | 203 | 82627 | 83250 | tetR(B) | P2180_RS00535 | WP_000088605.1 | 207 | Tetracycline resistance transcriptional repressor |
|        |                   |           |          |      |       |       |      | tet(B) | P2180_RS00540 | WP_001089068.1 | 401 | Tetracycline efflux MFS transporter |
|        |                   |           |          |      | tetC   | 84650 | 85244 | P2180_RS00545 | WP_000428546.1 | 197 | Tetracycline resistance-associated transcriptional repressor |

AMR, antimicrobial resistance; MFS, major facilitator superfamily.
also drug suspensibility testing based on globally accepted guidelines. The whole-genome sequencing technology should aim to offer immediate and accurate resistance information on the genetic level so that AMR/MDR strains could be identified in time, helping clinicians to initiate appropriate treatment strategies in a timely manner. Drug suspensibility testing should be conducted to discover Y. pestis strains with unknown drug resistance genes to avoid missing AMR/MDR isolates.

**Conclusion**

Y. pestis can acquire antibiotic resistance in nature not only via conjugative transfer of AMR plasmids from other bacteria, but also by gene point mutations. The health care system should enhance the surveillance of Y. pestis by taking measures to control transposon transmission and detect antibiotic-resistant strains with whole-genome sequencing and drug suspensibility testing. Discovering drugs targeting novel gene points is also of urgent importance considering drug-induced gene mutations.

**Notes**

**Ethics Approval**
Not applicable.

**Conflicts of Interest**
The authors have no conflicts of interest to declare.

**Funding**
None.

**Availability of Data**
All data generated or analyzed during this study are included in this published article. Other data may be requested through the corresponding author.

**Additional Contributions**
Management and Science University (Selangor, Malaysia) provided statistical support.

**References**

1. Butler T. Plague history: Yersin’s discovery of the causative bacterium in 1894 enabled, in the subsequent century, scientific progress in understanding the disease and the development of treatments and vaccines. Clin Microbiol Infect 2014;20:202–9.
2. Stenseth NC, Atshabar BB, Begon M, et al. Plague: past, present, and future. PLoS Med 2008;5:e3.
3. Kugeler KJ, Mead PS, Campbell SB, et al. Antimicrobial treatment patterns and illness outcome among United States patients with plague, 1942-2018. Clin Infect Dis 2020;70 Suppl 1:S20–6.
4. Ditchburn JL, Hodgkins R. Yersinia pestis, a problem of the past and a re-emerging threat. Biosaf Health 2019;1:65–70.
5. Titball RW, Hill J, Lawton DG, et al. Yersinia pestis and plague. Biochem Soc Trans 2003;31:104–7.
6. Susat J, Lubke H, Immel A, et al. A 5,000-year-old hunter-gatherer already plagued by Yersinia pestis. Cell Rep 2021;35:109278.
7. Parkhill J, Wren BW, Thomson NR, et al. Genome sequence of Yersinia pestis, the causative agent of plague. Nature 2001;413:523–7.
8. Deng W, Burland V, Plunkett G 3rd, et al. Genome sequence of Yersinia pestis KIM. J Bacteriol 2002;184:4601–11.
9. Song Y, Tong Z, Wang J, et al. Complete genome sequence of Yersinia pestis strain 91001, an isolate avirulent to humans. DNA Res 2004;11:179–97.
10. Chain PS, Hu P, Malfatti SA, et al. Complete genome sequence of Yersinia pestis strains Antiqua and Nepal516: evidence of gene reduction in an emerging pathogen. J Bacteriol 2006;188:4535–63.
11. Pisarenko SV, Evchenko AV, Kovalev DA, et al. Yersinia pestis strains isolated in natural plague foci of Caucasus and Transcaucasia in the context of the global evolution of species. Genomics 2021;113:1952–61.
12. Demeure C, Dussurget O, Fiol GM, et al. Yersinia pestis and plague: an updated view on evolution, virulence determinants, immune subversion, vaccination and diagnostics. Microbes Infect 2019;21:202–12.
13. Grabowski B, Schmidt MA, Rüter C. Immunomodulatory Yersinia outer proteins (Yops)-useful tools for bacteria and humans alike. Virulence 2017;8:1124-47.
14. Trosky JE, Liverman AD, Orth K. Yersinia outer proteins: Yops. Cell Microbiol 2008;10:557–65.
15. Pradel E, Lemaitre N, Merczeh M, et al. New insights into how Yersinia pestis adapts to its mammalian host during bubonic plague. PLoS Pathog 2014;10:e1004029.
16. Palace SG, Proulx MK, Lu S, et al. Genome-wide mutant fitness profiling identifies nutritional requirements for optimal growth of Yersinia pestis in deep tissue. mBio 2014;5:e01385-14.
17. Gage KL, Kosoy MY. Natural history of plague: perspectives from more than a century of research. Annu Rev Entomol 2005;50:505–28.
18. Yang R. Plague: recognition, treatment, and prevention. J Clin Microbiol 2017;56:e01519–17.
19. Bi Y. Immunology of Yersinia pestis infection. Adv Exp Med Biol 2016;918:273–92.
20. Shannon JG, Hasenkrug AM, Dorward DW, et al. Yersinia pestis subverts the dermal neutrophil response in a mouse model of bubonic plague. mBio 2013;4:e00170-13.
21. Spinner JL, Winfree S, Starr T, et al. Yersinia pestis survival and replication within human neutrophil phagosomes and uptake of infected neutrophils by macrophages. J Leukoc Biol 2014;95:389–98.
22. Zhang Y, Ying X, He Y, et al. Invasiveness of the Yersinia pestis ail protein contributes to host dissemination in pneumonia and oral plague. Microb Pathog 2020;141:103993.
23. Tsui PY, Tsai HP, Chiao DJ, et al. Rapid detection of Yersinia pestis recombinant fraction 1 capsular antigen. Appl Microbiol Biotechnol
Chen Lei et al.

24. Heath DG, Anderson GW Jr, Mauro JM, et al. Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine 1998;16:1313–7.

25. Hsu HL, Chuang CC, Liang CC, et al. Rapid and sensitive detection of Yersinia pestis by lateral-flow assay in simulated clinical samples. BMC Infect Dis 2018;18:402.

26. Singh R, Pai V, Tripathi NK, et al. Development of a pair of real-time loop mediated isothermal amplification assays for detection of Yersinia pestis, the causative agent of plague. Mol Cell Probes 2020;54:101670.

27. Born F, Braun P, Scholz HC, et al. Specific detection of Yersinia pestis based on receptor binding proteins of phages. Pathogens 2020;9:611.

28. Gerome P, Le Fleche P, Blouin Y, et al. Yersinia pseudotuberculosis ST42 (O:1) strain misidentified as Yersinia pestis by mass spectrometry analysis. Genome Announc 2014;2:e00435.

29. Butler T. Plague into the 21st century. Clin Infect Dis 2009;49:736–42.

30. Qu S, Shi Q, Zhou L, et al. Ambient stable quantitative PCR reagents for the detection of Yersinia pestis. PLoS Negl Trop Dis 2010;4:e629.

31. Randriantseheno LN, Rahantamalala A, Randrianierenana AL, et al. Development and evaluation of loop-mediated isothermal amplification for detection of Yersinia pestis in plague biological samples. PLoS One 2020;15:e0237655.

32. Gage RL, Dennis DT, Orloski KA, et al. Cases of cat-associated human plague in the Western US, 1977-1998. Clin Infect Dis 2000;30:893–900.

33. Anisimov AP, Amoako KK. Treatment of plague: promising alternatives to antibiotics. J Med Microbiol 2006;55:1461–75.

34. Riedel S. Plague: from natural disease to bioterrorism. Proc (Bayl Univ Med Cent) 2005;18:116–24.

35. Bin Saeed AA, Al-Hamdan NA, Fontaine RE. Plague from eating raw camel liver. Emerg Infect Dis 2005;11:1456–7.

36. Crook LD, Tempest B. Plague: A clinical review of 27 cases. Arch Intern Med 1992;152:1253–6.

37. Nelson CA, Meaney-Delman D, Fleck-Derderian S, et al. Antimicrobial treatment and prophylaxis of plague: recommendations for naturally acquired infections and bioterrorism response. MMWR Recomm Rep 2021;70:1–7.

38. Nelson CA, Fleck-Derderian S, Cooley KM, et al. Antimicrobial treatment of human plague: a systematic review of the literature on individual cases, 1937-2019. Clin Infect Dis 2021;70 Suppl 1:53–10.

39. World Health Organization (WHO). Interregional meeting on prevention and control of plague [Internet]. Geneva: WHO; 2008 [cited 2022 Feb 3]. Available from: https://www.who.int/csr/resources/publications/WHO_HSE_EPR_2008_3w.pdf.

40. Kool JL. Risk of person-to-person transmission of pneumonic plague. Clin Infect Dis 2005;40:1166–72.

41. Wang H, Cui Y, Wang Z, et al. A dog-associated primary pneumonic plague in Qinghai Province, China. Clin Infect Dis 2011;52:185–90.

42. Galimand M, Carniel E, Courvalin P. Resistance of Yersinia pestis to antimicrobial agents. Antimicrob Agents Chemother 2006;50:3233–6.

43. Wang X, Zhang X, Zhou D, et al. Live-attenuated Yersinia pestis vaccines. Expert Rev Vaccines 2013;12:677–86.

44. Triball RW, Williamson ED. Yersinia pestis (plague) vaccines. Expert Opin Biol Ther 2004;4:965–73.

45. Singh AK, Wang X, Sun W. Oral vaccination with live attenuated Yersinia pseudotuberculosis strains delivering a FliC180-LcrV fusion antigen confers protection against pulmonary Y. Pestis infection. Vaccine 2020;38:3720–8.

46. Review on Antimicrobial Resistance (AMR). Background [Internet]. London: AMR; [Unknown] [cited 2021 Nov 21]. Available from: https://amr-review.org/background.html.

47. Andriaivaonaarimanana V, Wagner DM, Birdsell DN, et al. Transmission of antimicrobial resistant Yersinia pestis during a pneumonic plague outbreak. Clin Infect Dis 2021 Jul 9 [Epub]. https://doi.org/10.1093/cid/ciab606.

48. Dai R, He J, Zha X, et al. A novel mechanism of streptomycin resistance in Yersinia pestis: Mutation in the rpsL gene. PLoS Negl Trop Dis 2021;15:e0009324.

49. Galimand M, Guiyoule A, Gerbad G, et al. Multidrug resistance in Yersinia pestis mediated by a transferable plasmid. N Engl J Med 1997;337:677–80.

50. Cabanel N, Bouchier C, Rajerson M, et al. Plasmid-mediated doxycycline resistance in a Yersinia pestis strain isolated from a rat. Int J Antimicrob Agents 2018;51:249–54.

51. Chanteau S, Ratsiorahina M, Rahalison L, et al. Current epidemiology of human plague in Madagascar. Microbes Infect 2000;2:25–31.

52. Kiefer D, Dalantai G, Damdindorj T, et al. Phenotypical characterization of Mongolian Yersinia pestis strains. Vector Borne Zoonotic Dis 2012;12:183–8.

53. He J, Yang X, Xin Y, et al. Establishment and application of a multiple drug resistance gene detection method of Yersina pestis. Chin J Endem 2018;37:207–11. Chinese.

54. Urich SK, Chalcraft L, Schriever ME, et al. Lack of antimicrobial resistance in Yersinia pestis isolates from 17 countries in the Americas, Africa, and Asia. Antimicrob Agents Chemother 2012;56:555–8.

55. Wang M, Tang XY, Yang YH. Progress in researches on drug-resistance of Yersinia pestis. Chin J Public Health 2019;35:925–9. Chinese.

56. Castro-Vargas RE, Herrera-Sanchez MP, Rodriguez-Hernandez R, et al. Antibiotic resistance in Salmonella spp. isolated from poultry: A global overview. Vet World 2020;13:2070–84.

57. Guiryoule A, Gerbad G, Buchriese C, et al. Transferable plasmid-mediated resistance to streptomycin in a clinical isolate of Yersinia pestis. Emerg Infect Dis 2001;7:43–8.

58. Welch TJ, Fricke WF, McDermott PF, et al. Multiple antimicrobial resistance in plague: an emerging public health risk. PLoS One 2007;2:e309.

59. Babakhani S, Oloomi M. Transposons: the agents of antibiotic resistance in bacteria. J Basic Microbiol 2018;58:905–17.

60. Dahayabay PS, Hossain S, Wickramanayake MVKS, et al. Antibiotic and heavy metal resistance genes in Aeromonas spp. isolated from marketed Manila Clam (Ruditapes philippinarum) in Korea. J Appl
61. Yau S, Liu X, Djordjevic SP, et al. RSF1010-like plasmids in Australian Salmonella enterica serovar Typhimurium and origin of their sul2-strA-strB antibiotic resistance gene cluster. Microb Drug Resist 2010;16:249–52.

62. Ludvigsen J, Amdam GV, Rudi K, et al. Detection and characterization of streptomycin resistance (strA-strB) in a honeybee gut symbiont (Snodgrassella alvi) and the associated risk of antibiotic resistance transfer. Microb Ecol 2018;76:588–91.

63. Shrestha D, Maharjan B, Thida Oo NA, et al. Molecular analysis of streptomycin-resistance associating genes in Mycobacterium tuberculosis isolates from Nepal. Tuberculosis (Edinb) 2020;125:101985.

64. Sreevatsan S, Pan X, Stockbauer KE, et al. Characterization of rpsL and rrs mutations in streptomycin-resistant Mycobacterium tuberculosis isolates from diverse geographic localities. Antimicrob Agents Chemother 1996;40:1024–6.

65. Finken M, Kirschner P, Meier A, et al. Molecular basis of streptomycin resistance in Mycobacterium tuberculosis: alterations of the ribosomal protein S12 gene and point mutations within a functional 16S ribosomal RNA pseudoknot. Mol Microbiol 1993;9:239–46.

66. Eddy JL, Gielda LM, Caulfield AJ, et al. Production of outer membrane vesicles by the plague pathogen Yersinia pestis. PLoS One 2014;9:e107002.

67. Wagner A. Cooperation is fleeting in the world of transposable elements. PLoS Comput Biol 2006;2:e162.

68. Omeershffudin UN, Kumar S. Bacterial DNA Adenine Methyltransferase as a Novel Drug Target for Antibiotics: Current Status and Future Drug Discovery Challenges. Int J Curr Microbiol Appl Sci 2019;8:2494–504.